Camrelizumab
Promising Early Antitumor Activity of Camrelizumab Plus Famitinib in Advanced Melanoma
SG Tylor
A Phase II trial presented at the 2023 ASCO Annual Meeting showed that combining the PD-L1 inhibitor camrelizumab with the ...
A Phase II trial presented at the 2023 ASCO Annual Meeting showed that combining the PD-L1 inhibitor camrelizumab with the ...